Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Dr. Philip McCarthy of Rosewell Park on Using Clinical Data to Determine Treatm

  • Broadcast in Health



Follow This Show

If you liked this show, you should follow CureTalks.

Dr. Philip McCarthy will be discussing how he and his team uses their own clinical data to determine treatment options, in conjunction with clinical trial data. Dr. McCarthy is the Director of the Blood & Marrow Transplant Program at Roswell Park Cancer Institute, and a Professor of Oncology. Dr. McCarthy has been a BMT physician and hematologist and oncologist since finishing fellowship training in 1989.

He has been the BMT Director at the RPCI since 1997. Hes a member of the Cancer and Leukemia Group B, Cooperative Clinical Trials Group, the Center for Institutional Research on Blood and Marrow Transplantation (CIRBMT) , as well as a member of the editorial board of the two BMT Journals. He has been a clinical investigator in oncology particularly in BMT for more than 20 years. He served as a chair or co-chair of many clinical trials and is a member of the protocol team for the ongoing BMT Clinical Trials Network study, and we will get into those studies as we go. Dr. McCarthy is a member of ASH and ASCO, and his research interests are devoted to developing new auto and allo treatments for hematological disorders including myeloma that will lead to improved patient outcomes and decreased toxicity.

Panelists: Gary Petersen, Jack Aiello, Cynthia Chmielewski and Lizzy Smith

CLICK HERE to REGISTER (or) Mail priya@trialx.com